H.B. Fuller Company

Fundamentals6.0
Price Action4.0
News Sentiment6.0
AI Rating
6.0

Key Drivers

  • Margin Expansion
  • Cash Flow
  • Debt Pressure

AI
AI Summary

6.0

FUL is increasingly a margin-and-portfolio execution story—not a volume recovery story—as pricing, mix, and the AMS medical-adhesives deal are improving earnings and cash flow, but soft end markets and ~4x pro forma leverage mean upside depends on clean integration and sustained price/cost discipline rather than demand rebound.

MarginExpansion
ExecutionRisk
Leverage‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

6.0

Key Financial Insights:

  • Margin Expansion
  • Cash Flow
  • Debt Pressure

FUL's margins and cash flow improved meaningfully, but heavy leverage, intangible-heavy assets, and only moderate valuation keep the risk/reward balanced.

margin
leverage

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Support holding
  • Resistance overhead

FUL has been in a clear downtrend over the last month, with lower highs and a drop below $60, while buyers are only now emerging around $57.28-$58.06, making the setup mixed to negative unless it reclaims $60-$63.25.

downtrend
stabilizing
Support Level: $57.28-$58.06
Resistance Level: $59.00-$60.00, then $63.25-$64.86

After peaking at $64.86, price slid in a steady pullback and recently stabilized near support

Sentiment & News

6.0

Key News Insights:

  • Earnings Beat
  • Margin Expansion
  • Medical Adhesives

H.B. Fuller posted a solid Q2 earnings beat with improving margins and cash generation, while its recommended acquisition of Advanced Medical Solutions adds strategic growth potential despite some deal opposition. #M&A‍

EarningsBeat

The quarter and acquisition news are broadly supportive for FUL, but near-term stock performance will likely depend on integration execution and how the market values the deal